Brukinsa (zanubrutinib) vs Vanflyta (quizartinib)

Brukinsa (zanubrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of mantle cell lymphoma and other B-cell malignancies, whereas Vanflyta (quizartinib) is a type II FLT3 inhibitor indicated for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with a FLT3-ITD mutation. The choice between these two medications would depend on the specific type of cancer a patient has, as they are not interchangeable and target different pathways involved in cancer cell proliferation. It is critical for a patient to consult with their oncologist to determine which medication is appropriate based on their cancer's genetic profile, disease stage, and overall health status.

Difference between Brukinsa and Vanflyta

Metric	Brukinsa (zanubrutinib)	Vanflyta (quizartinib)
Generic name	zanubrutinib	quizartinib
Indications	Mantle cell lymphoma (MCL) in adults who have received at least one prior therapy	Relapsed or refractory acute myeloid leukemia (AML) with FLT3-ITD mutations
Mechanism of action	Bruton's tyrosine kinase (BTK) inhibitor	Tyrosine kinase inhibitor, specifically inhibiting FLT3
Brand names	Brukinsa	Vanflyta
Administrative route	Oral	Oral
Side effects	Neutropenia, thrombocytopenia, anemia, diarrhea, cough, etc.	Febrile neutropenia, nausea, musculoskeletal pain, fatigue, QT prolongation, etc.
Contraindications	Hypersensitivity to zanubrutinib, severe hepatic impairment	Hypersensitivity to quizartinib, long QT syndrome, electrolyte abnormalities
Drug class	BTK inhibitor	FLT3 inhibitor
Manufacturer	BeiGene	Daiichi Sankyo

Efficacy

Brukinsa (Zanubrutinib) Efficacy in Leukemia

Brukinsa (zanubrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor that has shown efficacy in the treatment of certain types of leukemia. Specifically, it is used in the treatment of mantle cell lymphoma (MCL), a form of non-Hodgkin's lymphoma, which is a type of leukemia. Clinical trials have demonstrated that Brukinsa can lead to high response rates in patients with MCL. In these studies, the drug has been effective in shrinking tumors and in some cases, achieving complete remission. However, it is important to note that the efficacy can vary based on the stage of the disease and prior treatments received by the patient.

While Brukinsa is not currently approved for the treatment of other forms of leukemia, ongoing research and clinical trials may expand its use. Researchers are investigating the potential of zanubrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), with promising results in early-phase trials. These studies are crucial as they may provide more treatment options for patients with these types of leukemia.

Vanflyta (Quizartinib) Efficacy in Leukemia

Vanflyta (quizartinib) is a selective FLT3 inhibitor that has been studied for its efficacy in treating acute myeloid leukemia (AML), particularly in patients with the FLT3-ITD mutation. This mutation is associated with a poor prognosis in AML, and the presence of FLT3-ITD is a key driver in the proliferation of leukemic cells. Clinical trials have shown that quizartinib can significantly improve overall survival rates in patients with relapsed or refractory AML with the FLT3-ITD mutation when compared to chemotherapy. The drug's targeted approach allows for the inhibition of the FLT3 signaling pathway, which is crucial for the growth and survival of leukemic cells.

It is important to consider that the efficacy of Vanflyta may be influenced by factors such as the patient's mutation status, disease stage, and prior treatments. The use of quizartinib has been a significant advancement in the treatment of AML with FLT3-ITD mutation, providing a new line of therapy for patients who have limited treatment options. As with any medication, the efficacy of Vanflyta should be evaluated on an individual basis, and treatment decisions should be made in consultation with a healthcare professional specialized in the field of hematology and oncology.

Regulatory Agency Approvals

Brukinsa

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Vanflyta

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Brukinsa or Vanflyta today

If Brukinsa or Vanflyta are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Brukinsa

Buy Vanflyta

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: